Unique Wealth Strategies LLC Invests $1.84 Million in IQVIA Holdings Inc. (NYSE:IQV)

Unique Wealth Strategies LLC bought a new position in IQVIA Holdings Inc. (NYSE:IQV) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 7,956 shares of the medical research company’s stock, valued at approximately $1,841,000. IQVIA comprises about 1.2% of Unique Wealth Strategies LLC’s investment portfolio, making the stock its 18th biggest holding.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in IQV. AdvisorNet Financial Inc increased its stake in IQVIA by 327.6% during the fourth quarter. AdvisorNet Financial Inc now owns 124 shares of the medical research company’s stock worth $29,000 after acquiring an additional 95 shares during the last quarter. BKM Wealth Management LLC bought a new position in IQVIA in the fourth quarter worth approximately $32,000. Activest Wealth Management bought a new position in IQVIA in the fourth quarter worth approximately $35,000. CVA Family Office LLC bought a new position in IQVIA in the fourth quarter worth approximately $43,000. Finally, CoreFirst Bank & Trust purchased a new stake in IQVIA during the third quarter worth $44,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Analyst Ratings Changes

IQV has been the subject of a number of analyst reports. Barclays upped their target price on IQVIA from $260.00 to $265.00 and gave the stock an “overweight” rating in a report on Thursday, February 15th. Robert W. Baird upped their target price on IQVIA from $226.00 to $251.00 and gave the stock a “neutral” rating in a report on Thursday, February 15th. StockNews.com upgraded IQVIA from a “hold” rating to a “buy” rating in a report on Friday, February 16th. Truist Financial increased their price objective on IQVIA from $286.00 to $297.00 and gave the company a “buy” rating in a report on Tuesday, February 27th. Finally, UBS Group increased their price objective on IQVIA from $240.00 to $300.00 and gave the company a “buy” rating in a report on Thursday, February 15th. Three equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $256.80.

Insiders Place Their Bets

In other news, insider Ari Bousbib sold 31,678 shares of the firm’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $250.53, for a total transaction of $7,936,289.34. Following the sale, the insider now directly owns 796,752 shares in the company, valued at approximately $199,610,278.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, insider Kevin C. Knightly sold 8,607 shares of the firm’s stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $250.17, for a total transaction of $2,153,213.19. Following the sale, the insider now directly owns 5,251 shares in the company, valued at approximately $1,313,642.67. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Ari Bousbib sold 31,678 shares of the firm’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $250.53, for a total value of $7,936,289.34. Following the sale, the insider now owns 796,752 shares in the company, valued at $199,610,278.56. The disclosure for this sale can be found here. In the last three months, insiders have sold 41,285 shares of company stock valued at $10,331,003. Company insiders own 1.60% of the company’s stock.

IQVIA Stock Performance

Shares of NYSE IQV traded up $0.90 during mid-day trading on Friday, hitting $234.88. The stock had a trading volume of 697,640 shares, compared to its average volume of 761,918. The company has a 50 day moving average of $245.28 and a two-hundred day moving average of $223.02. The firm has a market cap of $42.63 billion, a PE ratio of 32.22, a PEG ratio of 2.26 and a beta of 1.50. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.86 and a current ratio of 0.86. IQVIA Holdings Inc. has a twelve month low of $167.42 and a twelve month high of $261.73.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Wednesday, February 14th. The medical research company reported $2.84 earnings per share for the quarter, topping the consensus estimate of $2.82 by $0.02. The company had revenue of $3.87 billion for the quarter, compared to the consensus estimate of $3.80 billion. IQVIA had a return on equity of 29.32% and a net margin of 9.06%. The firm’s revenue for the quarter was up 3.5% compared to the same quarter last year. During the same period last year, the firm earned $2.54 EPS. Research analysts predict that IQVIA Holdings Inc. will post 10.12 EPS for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.